Literature DB >> 15642996

Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana.

B Daan Westenbrink1, Ymkje Stienstra, Minke G Huitema, William A Thompson, Erasmus O Klutse, Edwin O Ampadu, H Marike Boezen, Piet C Limburg, Tjip S van der Werf.   

Abstract

Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, follows an indolent course of initial progression to ulceration accompanied by extensive tissue damage. It has been suggested that healing disease stages are accompanied by a protective immune response. We hypothesized that interleukin-4 (IL-4)- or IL-10-induced downregulation of Th-1 responses plays a key role in the progression of early BUD and that healing is accompanied by an augmented Th-1 response. Gamma interferon (IFN-gamma), IL-4, and IL-10 responses were measured after in vitro stimulation with phytohemagglutinin (PHA) and tuberculin purified protein derivative (PPD) of whole blood from 39 (23 early- and 16 late-stage) BUD patients and 39 healthy control subjects in Ghana. Additionally, 30 patients with active or treated tuberculosis (TB) serving as PPD-responsive positive controls were studied. Early-stage BUD patients produced significantly lower levels of IFN and IFN-gamma/IL-4 ratios compared to late-stage BUD patients after PHA stimulation. Compared to that of controls, IFN-gamma production after tuberculin stimulation was significantly higher in late-stage but not in early-stage BUD patients (P=0.009). IL-10 and IL-4 levels did not differ between BUD patients and controls, although active TB patients had significantly higher IL-10 production levels than did treated TB patients. Multivariate analysis showed no confounding factors. In conclusion, Th-1 down regulation in early BUD appears to reverse in later stages of BUD, although an association with IL-10 or IL-4 production does not emerge from our data. Here we show differences in Th-1-type cytokine production between early- and late-stage BUD that might reflect an improved immune defense over time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642996      PMCID: PMC540219          DOI: 10.1128/CDLI.12.1.125-129.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12.

Authors:  A Marchant; A Amedei; A Azzurri; J Vekemans; M Benagiano; C Tamburini; C Lienhardt; T Corrah; K P McAdam; S Romagnani; M M D'Elios; G Del Prete
Journal:  Am J Respir Cell Mol Biol       Date:  2001-02       Impact factor: 6.914

2.  Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10.

Authors:  A H van den Biggelaar; R van Ree; L C Rodrigues; B Lell; A M Deelder; P G Kremsner; M Yazdanbakhsh
Journal:  Lancet       Date:  2000-11-18       Impact factor: 79.321

3.  A role for IL-12 receptor expression and signal transduction in host defense in leprosy.

Authors:  J Kim; K Uyemura; M K Van Dyke; A J Legaspi; T H Rea; K Shuai; R L Modlin
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

Review 4.  Mycobacterium ulcerans infection.

Authors:  T S van der Werf; W T van der Graaf; J W Tappero; K Asiedu
Journal:  Lancet       Date:  1999-09-18       Impact factor: 79.321

Review 5.  Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors.

Authors:  Y Stienstra; W T van der Graaf; G J te Meerman; T H The; L F de Leij; T S van der Werf
Journal:  Trop Med Int Health       Date:  2001-07       Impact factor: 2.622

6.  Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy.

Authors:  C S Hirsch; Z Toossi; C Othieno; J L Johnson; S K Schwander; S Robertson; R S Wallis; K Edmonds; A Okwera; R Mugerwa; P Peters; J J Ellner
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

7.  IL-10-producing T cells suppress immune responses in anergic tuberculosis patients.

Authors:  V A Boussiotis; E Y Tsai; E J Yunis; S Thim; J C Delgado; C C Dascher; A Berezovskaya; D Rousset; J M Reynes; A E Goldfeld
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

8.  Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis.

Authors:  C H Song; H J Kim; J K Park; J H Lim; U O Kim; J S Kim; T H Paik; K J Kim; J W Suhr; E K Jo
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

9.  T regulatory cells 1 inhibit a Th2-specific response in vivo.

Authors:  F Cottrez; S D Hurst; R L Coffman; H Groux
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

10.  Immune response to infection with Mycobacterium ulcerans.

Authors:  T M Gooding; P D Johnson; D E Campbell; J A Hayman; E L Hartland; A S Kemp; R M Robins-Browne
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

View more
  20 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.

Authors:  Martinha S Oliveira; Alexandra G Fraga; Egídio Torrado; António G Castro; João P Pereira; Adhemar Longatto Filho; Fernanda Milanezi; Fernando C Schmitt; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.

Authors:  Egídio Torrado; Alexandra G Fraga; António G Castro; Pieter Stragier; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

4.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

Review 5.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

6.  Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity.

Authors:  Alvar Grönberg; Louise Zettergren; Kerstin Bergh; Mona Ståhle; Johan Heilborn; Kristian Angeby; Pamela L Small; Hannah Akuffo; Sven Britton
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

7.  Polymorphisms in TLR4 and TLR2 genes, cytokine production and survival in rural Ghana.

Authors:  Linda May; David van Bodegom; Marijke Frölich; Lisette van Lieshout; P Eline Slagboom; Rudi G J Westendorp; Maris Kuningas
Journal:  Eur J Hum Genet       Date:  2009-10-21       Impact factor: 4.246

8.  Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Authors:  Egídio Torrado; Sarojini Adusumilli; Alexandra G Fraga; Pamela L C Small; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

9.  Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.

Authors:  R Phillips; C Horsfield; S Kuijper; S F Sarfo; J Obeng-Baah; S Etuaful; B Nyamekye; P Awuah; K M Nyarko; F Osei-Sarpong; S Lucas; A H J Kolk; M Wansbrough-Jones
Journal:  Clin Vaccine Immunol       Date:  2006-02

10.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.